Ge fastlab

Manufactured by GE Healthcare

Sourced in United States, Belgium

The GE FASTlab is a compact and fully automated in-vitro diagnostic system designed for the preparation and analysis of samples in a clinical laboratory setting. The system's core function is to perform sample handling, reagent addition, and reaction monitoring to facilitate efficient and accurate diagnostic testing.

Automatically generated - may contain errors

Lab products found in correlation

Pu 2089 plus, by Elysia raytest (2 mentions) Md 2018 plus, by Elysia raytest (2 mentions) Luna c18, by Phenomenex (2 mentions) Biograph 64 truepoint pet ct system, by Siemens (1 mentions) Ge pettrace cyclotron, by GE Healthcare (1 mentions) Biograph truepoint 64, by Siemens (1 mentions) Ethanol, by Merck Group (1 mentions)

Close spelling variants of this product

GE FASTlab 2 Developer synthesis module GE Fastlab synthesis module FASTlab

8 protocols using ge fastlab

PET/CT Imaging of [11C]Acetate Uptake

Check if the same lab product or an alternative is used in the 5 most similar protocols

All patients underwent whole-body PET/CT scanning using a combined PET/CT in-line system (Biograph 64 TruePoint PET/CT system, Siemens, Erlangen, Germany). Patients were injected intravenously with approximately ~740 MBq to 850MBq of [¹¹C]Acetate based on the patient`s bodyweight, and uptake time was 20 minutes. [¹¹C]Acetate was prepared in-house using a fully automated radiosynthesizer (GE FASTlab^®, GE Healthcare, USA) with dedicated software and single-use cassettes produced under good manufacturing practice (GMP).
A supine PET dataset (4–5 bed positions, 3min/ bed position) from the base of the skull to mid-thigh and a low-dose, unenhanced CT scan (spiral scanning; Sl/pitch 3.0/0.55mm, 120kV, 230mAs) for attenuation correction and image registration was obtained. The PET data was reconstructed using the TRUE-X algorithm with four iterations (21 subsets, 168x168 Gaussian filter, FWHM 3mm).

Polanec S.H., Andrzejewski P., Baltzer P.A., Helbich T.H., Stiglbauer A., Georg D., Karanikas G., Susani M., Wadsak W., Margreiter M., Mitterhauser M., Brader P, & Pinker K. (2017). Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer. PLoS ONE, 12(7), e0180790.

+ Open protocol

+ Expand

Radiolabeling protocol for [18F]Me4FDG PET tracer

Check if the same lab product or an alternative is used in the 5 most similar protocols

[¹⁸F]Me4FDG was prepared in-house following a standardized protocol, using a GE FASTlab synthesizer (GE Healthcare, Boston, MA, USA) with dedicated disposable cassettes on the day of PET imaging. A regular cassette for [¹⁸F]FDG was used and prepared as follows: The FDG-precursor-vial was removed and exchanged to a 11 mL crimp-vial, filled with a solution of 10 mg GMP compliant precursor for Me4FDG (β-D-Galactopyranoside, methyl, 2,3,6-triacetate 4-trifluoromethanesulfonate, obtained from ABX advanced biochemical compounds GmbH, Radeberg, Germany) in 2 mL acetonitrile. Full radiopharmaceutical quality control according to the monographs of the European Pharmacopoeia (Ph. Eur.) was thoroughly performed prior the release of the tracer and application to the patient. The prepared cassette lost its GMP compliant due to the manipulation but since a radiosynthesis for a subsequent in-house application at the Vienna General Hospital is exempt from any GMP regulation, this route could be taken.

Geist B.K., Ramirez J.C., Binder P., Einspieler H., Ibeschitz H., Langsteger W., Nics L., Rausch I., Diemling M., Sohlberg A., Hacker M, & Rasul S. (2024). In vivo assessment of safety, biodistribution, and radiation dosimetry of the [18F]Me4FDG PET-radiotracer in adults. EJNMMI Research, 14, 46.

+ Open protocol

+ Expand

PET Tracer Synthesis and Quality Control

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The applied 2-[¹⁸F]fluoro-2-deoxyglucose ([¹⁸F]FDG) was produced in-house at the Interdisciplinary PET-Centre (IPZ) of the University Hospital Würzburg using the GE-PETtrace cyclotron and the GE-Fastlab^® synthesis unit (GE Medical Systems, Uppsala, Sweden) as previously described (Israel et al., 2016 ; Lapa et al., 2016 (link)). A computer-assisted synthesis-module (Scintomics, Fürstenfeldbruck, Germany) was used for the synthesis of [⁶⁸Ga]Ga-Fucoidan, as described previously (Li et al., 2014 (link)). Both radiotracers were manufactured under sterile conditions for clinical ([¹⁸F]FDG) and preclinical ([⁶⁸Ga]Ga-Fucoidan) applications and were analyzed for radiochemical purity by HPLC and TLC before application.

Schadt F., Israel I, & Samnick S. (2021). Development and Validation of a Semi-Automated, Preclinical, MRI-Template Based PET Image Data Analysis Tool for Rodents. Frontiers in Neuroinformatics, 15, 639643.

+ Open protocol

+ Expand

Automated Radiolabeling of PSMA-617 and RM2

Check if the same lab product or an alternative is used in the 5 most similar protocols

PSMA-617 and RM2 were radiolabeled with ¹¹¹In using an automated synthesizer (GE FastLab, GE Healthcare, GEMS Benelux, Belgium). Briefly, 40 μg of RM2 (Life Molecular Imaging) or PSMA-617 (ABX GmBH) was heated at 90 °C for 5 min using microwaves or ¹¹¹InCl₃ (CURIUM®) and 5 mg of ascorbic acid for RM2. The raw solution was then purified on a C₁₈ cartridge (WAT023501) preconditioned with 1 mL ethanol (Merck®) and 5 mL water (GE®). The final product was then eluted with 1 mL ethanol and formulated in PBS. ¹¹¹In-RM2 and ¹¹¹In-PSMA-617 were checked for radiochemical purity and amount using radio-UV-HPLC (Phenomenex Luna C₁₈; 250 mm × 4.6 mm × 5 μm; 2.5 mL/min, λ = 220 nm; eluent A comprising 0.1% TFA in water, eluent B comprising acetonitrile; gradient 0–10 min, 95% to 5% A). The analytical HPLC system used was a JASCO system with ChromNAV software, a PU-2089 Plus quaternary gradient pump, a MD-2018 Plus photodiode array detector, and Raytest Gabi Star detector.

Schollhammer R., De Clermont Gallerande H., Yacoub M., Quintyn Ranty M.L., Barthe N., Vimont D., Hindié E., Fernandez P, & Morgat C. (2019). Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples. EJNMMI Research, 9, 52.

+ Open protocol

+ Expand

Prone [18F]FDG PET/CT Imaging of Breast Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

[¹⁸F]FDG was prepared in-house using a fully automated radiosynthesizer (GE FASTlab®, GE Healthcare, USA) with dedicated software and single-use cassettes [32 (link)–33 (link)].
Prone [¹⁸F]FDG PET/CT of the breast was performed using a combined whole-body PET/CT in-line system (Biograph 64 TruePoint®; Siemens, Erlangen, Germany) equipped with a high-resolution PET scanner and a 64-row detector CT scanner. Prior to injection of the radiotracer, patients fasted for at least five hours. If plasma glucose was less than 150 mg/dl (8.3 mmol/l), each patient was injected intravenously with 200–350 MBq [¹⁸F]FDG based on body weight. After [¹⁸F]FDG injection, patients rested for a 60 min uptake period. This was followed by image acquisition where initially, a prone low-dose CT scan without contrast agent from the base of the skull to the upper abdominal region was acquired for attenuation correction and subsequently, a high-resolution, prone PET dataset was recorded over the same region. Raw data were reconstructed using an ordered subset expectation maximization (OSEM) algorithm with point spread function correction (PSF) correction (“TrueX”) [34 (link)–36 (link)]. Four iterations with 21 subsets were used, with a matrix size of 168×168 (pixel size 4.1 × 4.1 mm) and a slice thickness of 5 mm. No post-reconstruction filter was applied (“ALLPASS” option).

Magometschnigg H., Pinker K., Helbich T., Brandstetter A., Rudas M., Nakuz T., Baltzer P., Wadsak W., Hacker M., Weber M., Dubsky P, & Filipits M. (2019). PIK3CA Mutational Status is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging study using [18F]FDG PET/CT. Molecular imaging and biology, 21(5), 991-1002.

+ Open protocol

+ Expand

In-House Synthesis of PET Tracers

Check if the same lab product or an alternative is used in the 5 most similar protocols

[¹⁸F]FDG and [¹⁸F]fluoride were synthesized in house (GE FASTlab®; GE Healthcare, Piscataway, NJ, USA) with dedicated software and single‐use cassettes (FastLab Casettes, GE Healthcare).

Hayer S., Zeilinger M., Weiss V., Dumanic M., Seibt M., Niederreiter B., Shvets T., Pichler F., Wadsak W., Podesser B.K., Helbich T.H., Hacker M., Smolen J.S., Redlich K, & Mitterhauser M. (2019). Multimodal [18F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNFα Transgenic Mice. Journal of Bone and Mineral Research, 34(9), 1632-1645.

+ Open protocol

+ Expand

Synthesis and QC of Me-4-[18F]FDG Tracer

Check if the same lab product or an alternative is used in the 5 most similar protocols

Me-4-[¹⁸F]FDG was prepared in-house following a standardized protocol, using a GE FASTlab synthesizer (GE Healthcare, Boston, MA, USA) with dedicated disposable cassettes on the day of PET imaging. A regular FDG cassette was used and prepared as follows: The FDG-precursor-vial was removed and exchanged to a 11-mL crimp-vial, filled with a solution of 10 mg precursor for Me4FDG (β-d-galactopyranoside, methyl, 2,3,6-triacetate 4-trifluoromethanesulfonate, obtained from ABX advanced biochemical compounds GmbH, Radeberg, Germany) in 2 mL acetonitrile. Full radiopharmaceutical quality control according to the monographs of the European Pharmacopoeia (Ph. Eur.) was thoroughly performed prior to the release of the tracer and application to the patient. The production is not GMP compliant anymore but not necessary for in-house production within the General Hospital of Vienna.

Geist B.K., Brath H., Zisser L., Yu J., Fueger B., Nics L., Patronas E.M., Kautzky-Willer A., Hacker M, & Rasul S. (2023). Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus. European Journal of Nuclear Medicine and Molecular Imaging, 50(10), 3034-3041.

+ Open protocol

+ Expand

Automated Radiolabeling of RM2 Peptide

Check if the same lab product or an alternative is used in the 5 most similar protocols

Radiolabelling experiments were performed on an automated synthetisor (GE FastLab, GE Healthcare, GEMS Benelux, Belgium). Briefly, 40μg of RM2 (Life Molecular Imaging) was heated at 90°C during 5min using micro-waves with 1.1 mL ⁶⁸GaCl₃ (GalliEo generator with nominal activity of 1850 MBq, IRE Elit, Belgium) and 5mg of ascorbic acid. The raw solution was then purified on a C₁₈ cartridge (WAT023501) preconditioned with 1mL ethanol (Merck) and 5 mL water (GE Healthcare). The final product was then eluted with 1 mL ethanol and formulated in PBS. ⁶⁸Ga-RM2 was checked for radiochemical purity using HPLC (Phenomenex Luna C₁₈; 250mm x 4.6mm x 5μm; 2.5 mL/min, λ = 220nm). The analytical HPLC system used was a JASCO system with ChromNAV software, a PU-2089 Plus quaternary gradient pump, a MD-2018 Plus photodiode array detector and Raytest Gabi Star detector. Amount of ⁶⁸Ga-RM2 was determined by UV-HPLC by linear regression of the calibration curve established using the reference compound ^natGa-RM2 (Life Molecular Imaging).

Morgat C., Schollhammer R., Macgrogan G., Barthe N., Vélasco V., Vimont D., Cazeau A.L., Fernandez P, & Hindié E. (2019). Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. PLoS ONE, 14(1), e0210905.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!